PR Newswire
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
📈
AI Sentiment
Highly Positive
9/10
Johnson & Johnson News
Latest updates and market news for JNJ
20 news
Mar 17 - Mar 23, 2026
Page 1
MarketBeat
Protagonist Therapeutics Soars as FDA Approves ICOTYDE for Plaque Psoriasis, Triggers $50M Milestone
📈
AI Sentiment
Highly Positive
10/10
Insider Monkey
Jim Cramer on Johnson & Johnson: “It’s a Textbook Slowdown Stock”
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story
📊
AI Sentiment
Positive
7/10
Zacks
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why
📈
AI Sentiment
Highly Positive
9/10
Zacks
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
📈
AI Sentiment
Highly Positive
8/10
Financial Planning
After notable victories, anti-DEI shareholders turn sights on Trump's SEC
➖
AI Sentiment
Neutral
4/10
Packaging Gateway
Origin Materials and HP Embalagens enter PET cap distribution deal
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Johnson & Johnson Prostate Cancer Trial Adds Depth To Valuation Debate
📈
AI Sentiment
Highly Positive
8/10
Insider Monkey
Barclays Sees Continued Strength in Johnson & Johnson (JNJ) Pharma Business
📈
AI Sentiment
Highly Positive
9/10
PR Newswire
GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer
📈
AI Sentiment
Highly Positive
8/10
Business Wire
Origin Announces HP Embalagens as Strategic Distributor for Sustainable PET Bottlecaps
📈
AI Sentiment
Highly Positive
8/10
24/7 Wall St.
How Much Do you Need To Invest to Make $100k On Dividends Right Now?
➖
AI Sentiment
Neutral
5/10
Insider Monkey
Jim Cramer on Johnson & Johnson: “It Should Have Gone Higher, But It Just Shows You How Hard It Is to Buck Stagflation Theories”
📊
AI Sentiment
Positive
7/10
MT Newswires
Barclays Adjusts Price Target on Johnson & Johnson to $234 From $217, Maintains Equalweight Rating
📊
AI Sentiment
Positive
7/10
Motley Fool
2 Reasons to Buy Johnson & Johnson Stock Like There's No Tomorrow
📈
AI Sentiment
Highly Positive
9/10
Insider Monkey
HSBC Sees Healthcare Strength, Lifts Johnson & Johnson (JNJ) Price Target
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
ICOTYDE Approval Adds New Growth Angle To Johnson & Johnson Valuation Story
📈
AI Sentiment
Highly Positive
8/10
Share this news page